Catastrophic Antiphospholipid Syndrome Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Catastrophic Antiphospholipid Syndrome represents the most severe manifestation of antiphospholipid syndrome, a rare autoimmune disorder that triggers widespread thrombosis and rapid multi-organ failure, often triggered by infection, surgery, or medication withdrawal. The global CAPS market was valued at approximately $4.18 billion in 2025 and is on a growth trajectory driven by increasing clinical recognition and expanding treatment armamentarium. The condition, though rare, carries high clinical urgency and significant healthcare costs due to intensive care requirements and long-term management needs.

• •Estimated global market size of $4.18 billion in 2025, with steady year-on-year expansion
• •Characterized by ultra-rare prevalence but high treatment complexity and acute care resource utilization
• •Treatment pathways span acute management with anticoagulation, steroids, plasma exchange, and targeted biologics

Increasing awareness and recognition of CAPS among rheumatologists, hematologists, and intensivists is driving earlier diagnosis and intervention, expanding the treatable patient population. Advances in diagnostic criteria, including updated Sapporo classification standards and improved antiphospholipid antibody testing, have enhanced clinical identification of this previously underdiagnosed condition. The approval and off-label adoption of biologic therapies, particularly rituximab, have significantly improved survival rates and established a new standard of care, fueling market value growth.

• •Rising clinical awareness and physician education programs improving diagnosis rates across developed and emerging markets
• •Biologic therapies such as rituximab demonstrating improved outcomes and driving premium-priced treatment adoption
• •Growing pipeline of targeted therapies for antiphospholipid syndrome addressing unmet need in CAPS patient population

The market is segmented by treatment type, including anticoagulants, corticosteroids, plasma therapeutics, and biologic agents, with biologics representing the fastest-growing segment due to superior efficacy in refractory CAPS cases. North America commands the largest market share, supported by advanced healthcare infrastructure, high disease awareness, and favorable reimbursement frameworks. Europe follows, with strong clinical research activity, while the Asia-Pacific region is emerging as a growth area driven by improving diagnostic capabilities and expanding access to specialty therapies.

• •North America leads market share, supported by established healthcare systems and high specialty drug adoption
• •Europe represents a significant market with robust clinical trial activity and regulatory pathways for orphan drugs
• •Asia-Pacific is a fast-growing region driven by improving diagnostic infrastructure and increasing autoimmune disease prevalence

What are the recent trends and outlook?

The CAPS market is expected to maintain a compound annual growth rate of approximately 7.4% through the early 2030s, supported by continued biologics adoption and expanding indications for targeted autoimmune therapies. Emerging treatment paradigms combining complement inhibitors and next-generation B-cell targeting agents hold promise for improving outcomes in refractory CAPS cases. The ultra-orphan nature of the condition continues to attract regulatory incentives including orphan drug designation, fast-track pathways, and premium pricing, which collectively support sustained market growth despite the small patient population.

• •Projected CAGR of 7.4% through 2030, driven by biologics expansion and improved clinical management protocols
• •Regulatory orphan drug incentives and fast-track designations supporting innovation and premium pricing in this ultra-rare indication
• •Emerging pipeline of targeted biologics and complement inhibitors expected to further drive market growth and treatment personalization